Strychnine therapy in nonketotic hyperglycinemia

Area of Science:

• Biochemistry
• Neuroscience
• Genetics

Background:

• Nonketotic hyperglycinemia (NKH) is an inherited metabolic disorder caused by a defect in the glycine cleavage enzyme system.
• Biochemical hallmarks include elevated glycine concentrations in blood, cerebrospinal fluid (CSF), and urine.
• Previous therapeutic strategies targeting glycine reduction have failed to prevent neurological decline.

Observation:

• Glycine functions as an inhibitory neurotransmitter, potentially contributing to neurological deterioration in NKH.
• Strychnine was administered due to its specific antagonism of glycine at postsynaptic membranes.
• The patient received a combination therapy of strychnine and sodium benzoate.

Findings:

• The patient exhibited clinical improvement.
• Electroencephalogram (EEG) readings showed improvement during strychnine treatment.
• Combined therapy with strychnine and sodium benzoate was associated with positive outcomes.

Implications:

• Strychnine's antagonism of glycine offers a novel therapeutic approach for NKH.
• This case suggests that targeting glycine's neurotransmitter role may mitigate neurological damage.
• Further research into glycine antagonism could lead to more effective NKH treatments.